Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Leukemia, Myeloid, Chronic-Phase 34Leukemia 30Leukemia, Myeloid, Acute 18Leukemia, Lymphocytic, Chronic, B-Cell 13Blast Crisis 12Leukemia, Myeloid, Accelerated Phase 9Recurrence 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 7Multiple Myeloma 6Philadelphia Chromosome 5Myelodysplastic Syndromes 5Lymphoma, Non-Hodgkin 5Hematologic Neoplasms 5Lymphoma 4Hodgkin Disease 4Bronchiolitis Obliterans Syndrome 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

pertuzumab 1cc-486 1Trastuzumab 1Sirolimus 1Quality of Life 1Prednisone 1Patient Reported Outcome Measures 1Observation 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Injections 1Immunotherapy 1Genetic Profile 1Fluorodeoxyglucose F18 1FAPI-46 1Everolimus 1Drug Therapy 1Dasatinib 1Biological Therapy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Dasatinib × Other hematologic neoplasm × Clear all
NCT00563290 2015-06-18

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
7 enrolled 6 charts
DermatologicLymphoidOther hematologic neoplasm

Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡